<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042314</url>
  </required_header>
  <id_info>
    <org_study_id>CN156-008</org_study_id>
    <nct_id>NCT01042314</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study With Aricept® (Donepezil)</brief_title>
  <official_title>A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if the plasma concentration of donepezil is changed
      when BMS-708163 is administered at the same time
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aricept® alone and with BMS-708163: Aricept® Multiple-dose pharmacokinetic parameters (Cmax, Tmax, AUC (TAU), and Ctrough) will be assessed without BMS-708163 on Day 14 and with BMS-708163 (Ctrough) on Day 28</measure>
    <time_frame>Days 14 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aricept® alone and with BMS-708163: Safety and tolerability based on adverse events, ECG, vital signs and safety labs</measure>
    <time_frame>Days 7, 14, 21, 29 and study discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil and BMS-708163</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Tablets, Oral, 5 mg, Once Daily, Days 1-28</description>
    <arm_group_label>Donepezil and BMS-708163</arm_group_label>
    <other_name>Aricept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsule, Oral, 125 mg, Once Daily, Days 15-28</description>
    <arm_group_label>Donepezil and BMS-708163</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and postmenopausal women

        Exclusion Criteria:

          -  Medical History and Concurrent Diseases

          -  Gastrointestinal disease

          -  Gastrointestinal bleeding disorders

          -  History of peptic ulcer disease

          -  History of cholecystectomy

          -  History of seizure disorder

          -  History of asthma

          -  History of Chronic Obstructive Pulmonary Disease

          -  History of cardiac conduction abnormalities, including but not limited to &quot;sick sinus
             syndrome&quot; and those with unexplained syncopal episodes

          -  Inability to tolerate oral medication

          -  Inability to be venipunctured and/or tolerate venous access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International - Baltimore Epcu</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

